Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
Identifieur interne : 000087 ( France/Analysis ); précédent : 000086; suivant : 000088Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
Auteurs : Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France]Source :
- Expert opinion on drug safety [ 1474-0338 ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme, Médicament.
English descriptors
- KwdEn :
Abstract
Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000031
- to stream PascalFrancis, to step Curation: 000B87
- to stream PascalFrancis, to step Checkpoint: 000006
- to stream Main, to step Merge: 000B91
- to stream Main, to step Curation: 000B86
- to stream Main, to step Exploration: 000B86
- to stream France, to step Extraction: 000087
Links to Exploration step
Pascal:14-0095204Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Crispo, James" sort="Crispo, James" uniqKey="Crispo J" first="James" last="Crispo">James Crispo</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1><s2>Ottawa, Ontario, K1N 6N5</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ottawa, Ontario, K1N 6N5</wicri:noRegion></affiliation></author><author><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1><s2>Ottawa, Ontario, K1N 6N5</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ottawa, Ontario, K1N 6N5</wicri:noRegion></affiliation></author><author><name sortKey="Lapeyre Mestre, Marise" sort="Lapeyre Mestre, Marise" uniqKey="Lapeyre Mestre M" first="Marise" last="Lapeyre-Mestre">Marise Lapeyre-Mestre</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde</s1><s2>31000, Toulouse</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0095204</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0095204 INIST</idno><idno type="RBID">Pascal:14-0095204</idno><idno type="wicri:Area/PascalFrancis/Corpus">000031</idno><idno type="wicri:Area/PascalFrancis/Curation">000B87</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000006</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000006</idno><idno type="wicri:doubleKey">1474-0338:2014:Perez Lloret S:risk:of:heart</idno><idno type="wicri:Area/Main/Merge">000B91</idno><idno type="wicri:Area/Main/Curation">000B86</idno><idno type="wicri:Area/Main/Exploration">000B86</idno><idno type="wicri:Area/France/Extraction">000087</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Crispo, James" sort="Crispo, James" uniqKey="Crispo J" first="James" last="Crispo">James Crispo</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1><s2>Ottawa, Ontario, K1N 6N5</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ottawa, Ontario, K1N 6N5</wicri:noRegion></affiliation></author><author><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Ottawa, McLaughlin Centre for Population Health Risk Assessment, 1 Stewart Street</s1><s2>Ottawa, Ontario, K1N 6N5</s2><s3>CAN</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Ottawa, Ontario, K1N 6N5</wicri:noRegion></affiliation></author><author><name sortKey="Lapeyre Mestre, Marise" sort="Lapeyre Mestre, Marise" uniqKey="Lapeyre Mestre M" first="Marise" last="Lapeyre-Mestre">Marise Lapeyre-Mestre</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Hospital and University Paul Sabatier of Toulouse, France and INSERM CIC9023 and UMR 825, Department of Clinical Pharmacology and Neurosciences</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Faculty of Medicine, Department of Clinical Pharmacology, 37 Allées Jules Guesde</s1><s2>31000, Toulouse</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Expert opinion on drug safety</title><title level="j" type="abbreviated">Expert opin. drug saf.</title><idno type="ISSN">1474-0338</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Expert opinion on drug safety</title><title level="j" type="abbreviated">Expert opin. drug saf.</title><idno type="ISSN">1474-0338</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term><term>Bibliographic review</term><term>Cardiovascular disease</term><term>Dopamine agonist</term><term>Drug</term><term>Heart failure</term><term>Human</term><term>Neuroprotective agent</term><term>Parkinson disease</term><term>Pharmacovigilance</term><term>Pramipexole</term><term>Review</term><term>Risk factor</term><term>Toxicity</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Facteur risque</term><term>Insuffisance cardiaque</term><term>Traitement</term><term>Stimulant dopaminergique</term><term>Maladie de Parkinson</term><term>Homme</term><term>Toxicité</term><term>Médicament</term><term>Pathologie de l'appareil circulatoire</term><term>Pharmacovigilance</term><term>Pramipexole</term><term>Article synthèse</term><term>Revue bibliographique</term><term>Antiparkinsonien</term><term>Neuroprotecteur</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson's disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced dyskinesias. However, their utilization is limited by the risk of adverse drug reactions, some of which affect the cardiovascular system. Recently, the US FDA identified a possible association between exposure to pramipexole and the risk of heart failure. Areas covered: This article begins by reviewing the pharmacodynamic and cardiovascular effects of DAs on PD patients. Pharmacoepidemiological studies about the association between DAs and heart failure are then evaluated. Expert opinion: Four nested case-control studies were reviewed. In general, results showed higher heart failure risk following use of pramipexole or cabergoline. Although the effects of cabergoline may be explained by the induction of cardiac valve fibrosis, the basis for the significantly increased risk associated with pramipexole is unclear. It remains to be determined if these are dose-related effects, at what point they occur during the course of treatment, and if the risk is the same for all patients irrespective of other potential modifying factors, such as age and sex.</div></front></TEI><affiliations><list><country><li>Canada</li><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name></region><name sortKey="Lapeyre Mestre, Marise" sort="Lapeyre Mestre, Marise" uniqKey="Lapeyre Mestre M" first="Marise" last="Lapeyre-Mestre">Marise Lapeyre-Mestre</name><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name></country><country name="Canada"><noRegion><name sortKey="Crispo, James" sort="Crispo, James" uniqKey="Crispo J" first="James" last="Crispo">James Crispo</name></noRegion><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000087 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000087 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= France
|étape= Analysis
|type= RBID
|clé= Pascal:14-0095204
|texte= Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
}}
| This area was generated with Dilib version V0.6.29. |  |